PATENT CLAIM ANALYSIS

Application Number: 15942110
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "025000"]

Abstract:
The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.

Claim (Index 1):
An intranasal pharmaceutical composition comprising a suitable nontoxic, nonionic alkyl glycoside in combination with a compound that affects the central nervous system, wherein the compound is an anti-seizure agent, wherein the alkyl glycoside comprises dodecyl-\u03b2-D maltoside at a concentration in the range of about 0.01% to 1.0%, and wherein the dodecyl-\u03b2-D maltoside increases absorption and bioavailability of the compound in cerebrospinal fluid (CSF) of a subject.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 90.0
- Lexical Diversity: 1.54348
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15890131', '14133350', '15655669', '12341696', '12645376']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.881651393124556
- 35 USC 102 Novelty (BERT): 0.5887987499943239
- Combined Prediction Score: 0.8523661288115327
- Mean Citation Score: 581.9066799999998
- Max Citation Score: 608.0205
- Similarity Product: 409.82822891896967

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test